Product Description
CHK1 (Checkpoint kinase 1) is a member of the serine/threonine kinase family that plays a pivotal role in DNA damage response, cell cycle regulation, and genomic stability maintenance. CHK1 is activated by ATR in response to replication stress and DNA damage, leading to phosphorylation of key effectors such as CDC25 phosphatases and WEE1, resulting in cell cycle arrest at the S and G2/M checkpoints to allow DNA repair. Beyond its essential physiological functions in normal cell division, dysregulation of CHK1 signaling—including overexpression, hyperactivation, and aberrant checkpoint control—is frequently observed in various human cancers, enabling tumor cells to tolerate replication stress, evade apoptosis, and acquire chemoresistance. These features have established CHK1 as a highly validated target for cancer therapy, particularly in combination with DNA-damaging agents and as a synthetic lethality strategy.
Screeningbio’s CHK1 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying CHK1 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: CHK1 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the CHK1 kinase.
Data